M&A Deal Summary

Lilly Acquires Morphic

On July 8, 2024, Lilly acquired life science company Morphic

Acquisition Highlights
  • This is Lilly’s 27th transaction in the Life Science sector.
  • This is Lilly’s 29th transaction in the United States.
  • This is Lilly’s 8th transaction in Massachusetts.

M&A Deal Summary
Date 2024-07-08
Target Morphic
Sector Life Science
Buyer(s) Lilly
Deal Type Add-on Acquisition
Advisor(s) Centerview Partners
Evercore Group (Financial)
Fenwick & West (Legal)

Target

Morphic

Waltham, Massachusetts, United States
Morphic is a biopharmaceutical company developing a portfolio of oral integrin therapies for treating serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. The company is also advancing its pipeline and discovery activities in collaboration with Schrödinger using its proprietary MInT technology platform that leverages Morphic's unique understanding of integrin structure and biology. Morphic is based in Waltham, Massachusetts.

Search 197,704 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Lilly

Indianapolis, Indiana, United States
Category Company
Founded 1876
Sector Life Science
Employees43,000
Revenue 34.1B USD (2023)
DESCRIPTION
Entrance to Eli Lilly's campus in Indianapolis, Indiana.
Entrance to Eli Lilly's campus in Indianapolis, Indiana.

Lilly discovers, develops, manufactures, and markets products in two business segments—human pharmaceutical products and animal health products. The mission of its human pharmaceutical business is to make medicines that help people live longer, healthier, more active lives. Most of the products Eli Lilly sells were discovered or developed by its own scientists, and the Company's success depends to a great extent on its ability to continue to discover, develop, and bring to market innovative new medicines. Eli Lilly's animal health business, operating through its Elanco division, develops, manufactures, and markets products for both food animals and companion animals. Eli Lilly manufactures and distributes its products through facilities in the US, Puerto Rico, and 11 other countries. Lilly was founded in 1876 and is based in Indianapolis, Indiana.

DEAL STATS #
Overall 34 of 34
Sector (Life Science) 27 of 27
Type (Add-on Acquisition) 27 of 27
State (Massachusetts) 8 of 8
Country (United States) 29 of 29
Year (2024) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-12-18 Point Biopharma Global

Indianapolis, Indiana, United States

Point Biopharma Global is a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. Point Biopharma Global is based in Indianapolis, Indiana.

Buy -
Mergr

Product

Company

Legal